IMA vs PFE · rev $9.2M vs P/E 20, rev $62.58B
ImageneBio, Inc. (IMA) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported IMA revenue for 2023-12-31 was $9.2M. Net income was -$68.2M. Revenue was down 41.3% from 2022-12-31 to 2023-12-31. IMA currently screens at market cap $64.7M.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
IMA currently screens at market cap $64.7M. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the IMA and PFE stock pages for the full models.
Not investment advice.